Status:
COMPLETED
Cerebrospinal Fluid (CSF) Raltegravir Substudy
Lead Sponsor:
University of California, San Diego
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
HIV Infections
Eligibility:
All Genders
Brief Summary
The purpose of this study is to measure concentrations of Raltegravir in cerebrospinal fluid. The hypotheses are: * Raltegravir concentrations in CSF will be measurable * Raltegravir concentrations ...
Eligibility Criteria
Inclusion
- Enrollment in a raltegravir parent protocol at UCSD.
- Willing to undergo lumbar puncture.
- Able to give informed consent. If cognitively impaired, a test will be administered to ensure adequate comprehension of the consent document and procedure.
Exclusion
- Relative or absolute contraindication to lumbar puncture, such as current coagulopathy, thrombocytopenia (platelets\<50,000/µL), hemophilia, or use of anticoagulant medication.
- Psychiatric disease that would interfere with study participation, in the opinion of the investigator.
- No major opportunistic infections within 30 days.
- Moderate or severe cognitive impairment. The proposed study does not have a neuropsychological objective.
Key Trial Info
Start Date :
July 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2011
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT00718029
Start Date
July 1 2008
End Date
February 1 2011
Last Update
August 13 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.